Author + information
- Tatsuya Shiraki,
- Osamu Iida,
- Tomoharu Dohi,
- Takayuki Ishihara,
- Kiyonori Nanto,
- Takuma Iida and
- Masaaki Uematsu
The BASIL investigators reported that overall survival and amputation–free survival were not different at 2–year after endovascular therapy (EVT)–first or bypass surgery (BSX)–first revascularization strategies for patients with critical limb ischemia (CLI). However, beyond 2 years there appeared to be a benefit for BSX.
Between January 2007 and December 2011, 459 consecutive patients with CLI who underwent first EVT (396 patients) or BSX (63 patients) were enrolled, and assigned to two groups; alive at > 2–year or dead within 2–year. Multivariate analysis was performed to explore independent mortality determinants and risk stratification.
Baseline characteristics included patient age (72±10yrs), diabetes mellitus (68%, 313/459) and end stage renal disease (ESRD) on dialysis (47%, 215/459). Death occurred in 84 patients within 2–year. Non–ambulatory status (odds ratio [OR], 4.09; 95% confidence interval [CI], 2.00–8.34), ESRD on dialysis (OR, 2.15; 95% CI, 1.10–4.19) and left ventricular (LV) dysfunction (OR, 2.86; 95% CI, 1.38–5.89) were negatively associated with predictors of 2–year mortality. Based on stratification of patient survival according to the number of risk factors, it was lower in higher risk group. (Figure)
The predictors of mortality within 2 years after EVT or BSX for patients with CLI are non–ambulatory status, ESRD on dialysis and LV dysfunction. Risk stratification allows estimation of 2–year mortality in patients with CLI.
Moderated Poster Contributions
Poster Sessions, Expo North
Monday, March 11, 2013, 9:45 a.m.–10:30 a.m.
Session Title: Vascular Medicine: Endovascular Therapy IV
Abstract Category: 34. Vascular Medicine: Endovascular Therapy
Presentation Number: 1298M–169
- 2013 American College of Cardiology Foundation